Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benefit of allogeneic transplantation in patients age = 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.

Benefit of allogeneic transplantation in patients age = 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. Biol Blood Marrow Transplant. 2014 Apr; 20(4):474-9.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.